Evidence map›Paper›PMID 31083694›Full record

ArticlePLoS pathogens2019

Roles for E1-independent replication and E6-mediated p53 degradation during low-risk and high-risk human papillomavirus genome maintenance.

Isao Murakami, Nagayasu Egawa, Heather Griffin, Wen Yin, Christian Kranjec, Tomomi Nakahara, Tohru Kiyono, John Doorbar

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Deciphering the Role of Mast Cells in HPV-Related Cancers.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. REBACINFrontiers in oncology · 2022
    Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Isao MurakamiDepartment of Pathology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.
Nagayasu EgawaDepartment of Pathology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.
Heather GriffinDepartment of Pathology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.
Wen YinDepartment of Pathology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.
Christian KranjecDepartment of Pathology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.ORCID 0000-0001-9713-7406
Tomomi NakaharaDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-2342-6675
Tohru KiyonoDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0003-1769-403X
John DoorbarDepartment of Pathology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.ORCID 0000-0002-4027-102X
University of Cambridge · GBGenesis Research Institute · JPKeio University · JP

Funding

Medical Research Council MC_PC_13050Medical Research Council MC_U117584278Medical Research Council MR/S024409/1
6 · The paper itself

Abstract

Human papillomaviruses (HPV) have genotype-specific disease associations, with high-risk alpha types causing at least 5% of all human cancers. Despite these conspicuous differences, our data show that high- and low- risk HPV types use similar approaches for genome maintenance and persistence. During the maintenance phase, viral episomes and the host cell genome are replicated synchronously, and for both the high- and low-risk HPV types, the E1 viral helicase is non-essential. During virus genome amplification, replication switches from an E1-independent to an E1-dependent mode, which can uncouple viral DNA replication from that of the host cell. It appears that the viral E2 protein, but not E6 and E7, is required for the synchronous maintenance-replication of both the high and the low-risk HPV types. Interestingly, the ability of the high-risk E6 protein to mediate the proteosomal degradation of p53 and to inhibit keratinocyte differentiation, was also seen with low-risk HPV E6, but in this case was regulated by cell density and the level of viral gene expression. This allows low-risk E6 to support genome amplification, while limiting the extent of E6-mediated cell proliferation during synchronous genome maintenance. Both high and low-risk E7s could facilitate cell cycle re-entry in differentiating cells and support E1-dependent replication. Despite the well-established differences in the viral pathogenesis and cancer risk, it appears that low- and high-risk HPV types use fundamentally similar molecular strategies to maintain their genomes, albeit with important differences in their regulatory control. Our results provide new insights into the regulation of high and low-risk HPV genome replication and persistence in the epithelial basal and parabasal cells layers. Understanding the minimum requirement for viral genome persistence will facilitate the development of therapeutic strategies for clearance.

Indexed as

Genome, ViralVirus ReplicationCells, CulturedDNA, ViralHumansKeratinocytesOncogene Proteins, ViralPapillomaviridaePapillomavirus InfectionsPlasmidsTumor Suppressor Protein p53DNA, ViralOncogene Proteins, ViralTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID31083694
PMCPMC6544336
OpenAlexW2945410212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.